Cross-talk between calpain and caspase-3 in penumbra and core during focal cerebral ischemia-reperfusion

被引:33
作者
Sun, Ming [1 ]
Zhao, Yumei [1 ]
Xu, Chao [1 ]
机构
[1] Beijing Neurosurg Inst, Dept Neurochem, Beijing 100050, Peoples R China
关键词
focal cerebral ischemia-reperfusion; calpain; calpastatin; caspase-3; cross-talk;
D O I
10.1007/s10571-007-9250-1
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims Some data have shown the functional connection between calpain and caspase-3. Here, we investigated the cross-talk between calpain and caspase-3 in penumbra and core during focal cerebral ischemia-reperfusion. Methods The activities of calpain and the levels of calpastatin, microtubule-associated protein-2 (MAP-2), and spectrin in penumbra and core at 3 or 23 h of reperfusion (R 3 h or R 23 h) after 1-h focal cerebral ischemia in rats were determined in sham- or caspase-3 inhibitor z-DEVD-CHO-treated rats.On the other hand, the determination of the activities of caspase-3 and the levels of MAP-2 and spectrin was done in sham- or calpain-inhibitor I-treated rats. Results z-DEVD-CHO (600 ng/rat, i.c.v.) markedly reduced the mu- and m-calpain activities in penumbra and the m-calpain activities in core at R 3 h and R 23 h, and enhanced the calpastatin levels in penumbra at R 3 h and in core at R 3 h and R 23 h significantly; however, it had no significant effects on the mu-calpain activities in core and the calpastatin levels in penumbra at R 23 h. Calpain inhibitor I (0.8 mg/rat, i.c.v.) markedly reduced the caspase-3 activities in core at R 3 h and R 23 h, but not in penumbra. Both calpain and caspase-3 inhibitors increased the levels of MAP-2 and spectrin in penumbra and core significantly after focal cerebral ischemia-reperfusion. Conclusions Our data provide direct evidence to demonstrate the cross-talk between calpain and caspase-3 in penumbra and core during focal cerebral ischemia-reperfusion.
引用
收藏
页码:71 / 85
页数:15
相关论文
共 58 条
  • [1] Core and penumbral nitric oxide synthase activity during cerebral ischemia and reperfusion
    Ashwal, S
    Tone, B
    Tian, HR
    Cole, DJ
    Pearce, WJ
    [J]. STROKE, 1998, 29 (05) : 1037 - 1046
  • [2] Phosphorylation of rat brain calpastatins by protein kinase C
    Averna, M
    De Tullio, R
    Salamino, F
    Melloni, E
    Pontremoli, S
    [J]. FEBS LETTERS, 1999, 450 (1-2) : 13 - 16
  • [3] Specific caspase pathways are activated in the two stages of cerebral infarction
    Benchoua, A
    Guégan, C
    Couriaud, C
    Hosseini, H
    Sampaïo, N
    Morin, D
    Onténiente, B
    [J]. JOURNAL OF NEUROSCIENCE, 2001, 21 (18) : 7127 - 7134
  • [4] Ca2+ signals and death programmes in neurons
    Berliocchi, L
    Bano, D
    Nicotera, P
    [J]. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2005, 360 (1464) : 2255 - 2258
  • [5] Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO
  • [6] 2-C
  • [7] In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration -: Implication of a calpain-mediated cleavage of active caspase-3
    Bizat, N
    Hermel, JM
    Humbert, S
    Jacquard, C
    Créminon, C
    Escartin, C
    Saudou, F
    Krajewski, S
    Hantraye, P
    Brouillet, E
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (44) : 43245 - 43253
  • [8] Calpastatin is up-regulated in response to hypoxia and is a suicide substrate to calpain after neonatal cerebral hypoxia-ischemia
    Blomgren, K
    Hallin, U
    Andersson, AL
    Puka-Sundvall, M
    Bahr, BA
    McRae, A
    Saido, TC
    Kawashima, S
    Hagberg, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (20) : 14046 - 14052
  • [9] Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia - A mechanism of "pathological apoptosis"?
    Blomgren, K
    Zhu, CL
    Wang, XY
    Karlsson, JO
    Leverin, AL
    Bahr, BA
    Mallard, C
    Hagberg, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) : 10191 - 10198
  • [10] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3